Slides
Page 1
Vitrafy Life Sciences Pioneering Technology, Preserving Life. Building the foundational infrastructure for the global biologics economy. October 2026 Investor Roadshow ASX: VFY | October 2026 | vitrafy.com | Strictly Private & Confidential
Page 2
Important Notice and Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 7 October 2026 and should not be relied upon by the recipient. This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient. Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company. No liability To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company’s securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. Eligible recipients This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Confidentiality This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation. Not financial product advice Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not financial product or investment advice or a recommendation to acquire the Company’s securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in the Company and should not rely on this presentation. In all cases, you should conduct your own research of the Company and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction. Past performance Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as an indication of (and gives no guidance as to) future performance. Future performance This presentation contains certain forward-looking statements (including financial forecasts) with respect to the financial condition, operations and business of the Company and certain plans and objectives of the management of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects, “predicts”, “intends”, “plans”, “goals”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts. Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, the Company and its respective affiliates and related bodies corporate and each of their respective Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). Financial data All figures in the presentation are Australian dollars ($ or A$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. Financial information The pro forma financial information provided in this presentation is for illustrative purposes only and does not represent a forecast or expectation as to the Company’s future financial condition and/or performance. This document has been prepared at a time where the review of financial information contained in this presentation has not been completed and accordingly, you should only rely on any expectation as to the Company’s future financial condition and/or performance that is contained in a prospectus or other offering document which may be issued by the Company in connection with any offer of the Company’s securities. Acknowledgement Persons who access, receive, review or attend this presentation are required to inform themselves of, and comply with, all of the above restrictions and prohibitions and none of the Company or the Related Parties accepts any liability to any person in relation thereto. This presentation is made to you on the basis that by attending, accessing or receiving or reviewing this presentation, you confirm that you understand and agree to the contents of this important notice and disclaimer and that you are a person to whom this presentation may lawfully be made in accordance with laws applicable to you, including those of the jurisdiction in which you are located. 2
Page 3
Company Highlights Foundational infrastructure for the global biologics economy. Cryopreservation-as-an- Ecosystem • End-to-end cryopreservation solution • IP-protected hardware and software • Competitive moat deepens once installed Significant Validation & Commercial Adoption • U.S. Army studies I & II complete • Vitalant, Hoxworth & Versiti: three U.S. civilian blood partners • IMV Technologies: pathway to global scale in animal reproduction High-Margin Business Model • Monthly recurring fee covering device, software and service • Consumables scale with volume • Customer-centric, outcome-focused Step-Change in Scientific Outcomes • Exceeds several existing guidance standards • 94% post-thaw platelet recovery • Proven outcomes across several biological materials. Upcoming Catalysts • FDA medical device listing - 510(k) exempt • Civilian blood partner deployment • Human health commercialisation • U.S. operations scale-up (including CEO relocation) Critical Market Need • End-of-life products driving replacement across the U.S. blood network • One platform, multiple markets • Priority market: blood, animal reproduction, cell & gene therapy 3 Note: FY27 Ecosystem availability is limited to the Guardion cryopreservation freezer and LifeChain software for research and commercial use, subject to applicable FDA regulatory requirements. The Guardion thawer and consumables will be subject to future product releases.
Page 4
H I G H L I G H T S Execution of Key Milestones Vitrafy has executed across product, market development and operations since listing. Market Commercial Partnerships Delivered USAISR Platelets Study Delivered U.S. Market Foundation & Establishment Product Guardion & LifeChain Delivered Guardion Device Fleet Build-out Commenced Guardion FDA Regulatory Approval Financial $41.2m Total cash and term deposits as at 30 June 2026 Successful Capital Raise Strong YoY Revenue Growth 4 CommencedDelivered Delivered Delivered
Page 5
H I G H L I G H T S Scientific Validation, Commercial Momentum A year of scientific validation converted into partnerships, revenue and developing capacity. 94.4% Post-thaw platelet recovery — USAISR Study II 7 Partnerships signed across three sectors ~179 U.S. blood collection sites, exposure via partnership 10 First Guardion units built; fleet scale-up through FY27 Partnerships signed: ~$1.0m Contracted revenue across FY26 & FY27 159% FY26 animal revenue growth, year-on- year to $169k 7 U.S. headcount added; significant growth planned in FY27 5
Page 6
Operational Progress 06
Page 7
O P E R A T I O N A L P R O G R E S S Blood: Validation & Commercial Traction USAISR-validated performance converted into first civilian blood-network agreement. USAISR 94.4% Mean post-thaw, no-wash platelet recovery — USAISR Study II vs. USA fresh guideline 75% vs. European standard 50% Best-in-class recovery, exceeding both benchmarks. Q1 FY26 Blood validation expanded Study I results co-presented at AABB Conference; U.S. Study II platelet program commenced. Q2 FY26 U.S. platform established North American blood-market expertise added; U.S. operations established for customer demonstrations and conference presentation. Q3 FY26 Civilian demand signal USAISR Study II platelet program completed at 94.4% mean post-thaw, no-wash recovery. Civilian blood networks began direct engagement as the legacy RBC cryopreservation issue emerged. Q4 FY26 Commercial conversion Agreements entered into with key blood collection organisations Vitalant and Hoxworth; Significant recognition from industry bodies as Vitrafy as potential next-generation solution. 7
Page 8
O P E R A T I O N A L P R O G R E S S CGT: Pipeline Development From market launch to an advancing pipeline - approaching with first partnership secured. 1 Building the pipeline Ongoing CGT prioritised for U.S. launch; business development and prospective partner conversations well advanced. 2 Launch to market FY26 milestone First public exhibition at Phacilitate (Advanced Therapies Week); CDMOs and therapy developers engaged. 3 First CGT agreement partnership secured Q1 FY27 milestone Partnership with Charter Medical for use in cell & gene therapy U.S. Cell & Gene Therapy Market U.S. CGT market opportunity • ~1,800 manufacturers¹ in North America • ~300 CDMOs² operating in the space • Focussed on T-cell therapies and PBMCs Vitrafy expects to build out CGT deployments across FY27. 1. kenresearch.com, U.S. healthcare contract development & manufacturing market. 2. pfizercentreone.com, CDMO market trends & dynamics. 8
Page 9
O P E R A T I O N A L P R O G R E S S Animal Reproduction FY26 saw continued validation across new and existing partners in animal reproduction. Commercial growth • Global partnership secured with IMV Technologies to co- develop a global go-to-market offering. • In aquaculture, continued validation of the market opportunity with existing-partner growth. • FY27 will see ongoing bovine and aquaculture work with IMV and existing domestic aquaculture partners. Partners $0 $20,000 $40,000 $60,000 $80,000 $100,000 $120,000 $140,000 $160,000 $180,000 2023 2024 2025 2026 Animal health revenue (A$) The Company's ability to generate revenue pre-commercialisation and pre-scale is viewed as important commercial de-risking. 9
Page 10
O P E R A T I O N A L P R O G R E S S Product: Delivery Guardion freezing device and LifeChain software delivered in FY26, with key regulatory milestone work commenced. Guardion freezing device • Successful transition from design concept into Research Use Only (RUO) device manufacturing. • First manufactured units delivered in Q2 2026. • RUO status unlocking the initial commercial market opportunity. LifeChain software • Enterprise cloud platform released alongside Guardion. • Enables integrated device control and workflow orchestration. • Built to 21 CFR Part 11 compliance. 10
Page 11
O P E R A T I O N A L P R O G R E S S Product: Regulatory Approval Guardion and LifeChain have achieved significant development milestones, with FDA Medical Device listing expected 1H FY27. Milestone Research Use Guardion designed, developed and manufactured for research use — the first commercial product release milestone. LifeChain software built to 21 CFR Part 11 compliance, an FDA and industry software expectation. → Commenced Validation & Verification (medical device preparation work) Structured engineering and biological testing to meet FDA requirements. Verification — engineering. Validation — biological and user. FY27 Medical Device FDA Class 2 510(k) exempt listing – clearing a key regulatory hurdle to market access. → 11
Page 12
O P E R A T I O N A L P R O G R E S S Product: Manufacturing Scaling manufacturing ahead of commercial adoption and regulatory approval. Fleet & device builds • 10 units built across FY26 — used in testing, deployed to IMV and to support U.S. sales activities. • A further 15 units scheduled across 1H FY27, for commercial and medical-device use. • U.S. manufacturing operations commence 1H FY27, scaling capacity to supply announced partnerships and future commercial demand. 0 5 10 15 20 25 30 0 2 4 6 8 10 12 Q2 Q3 Q4 Q1 Q2 Cumulative Devices Built Devices Built per Quarter Guardion Manufacturing Schedule FY26 FY27 = Devices built per Quarter = Cumulative Total Devices 12
Page 13
O P E R A T I O N A L P R O G R E S S U.S. Operations U.S. foundations have been established to support growth into FY27. U.S. customer demonstration site active Key leadership hires across commercial and scientific functions First product reveal at a U.S. conference Onboarding, training and customer success programs active COO (U.S. based) hired in Q1 FY27 13 CEO relocating to U.S. in 1H FY27
Page 14
M A R K E T C O N T E X T Critical Market: Blood Two critical structural problems, demanding immediate market change. 18
Page 15
C R I T I C A L M A R K E T : B L O O D Rising Demand, Constrained Supply Demand is rising and supply is tightening. The gap is structural, not cyclical. Supply constrained Supply Constrained Declining Donation Rate 40% decline over last 20 years Shrinking, Ageing Donor Base ~3% of eligible population donates blood annually Majority of donors > 50 years old Product Expires Before Use Short shelf-life drives wastage Demand Rising Ageing Population More transfusions per patient Increased event driven volatility Surge capacity required on demand New Therapies Personalised products – such as Blood for Cell & Gene Therapies 15
Page 16
A Blood Crisis American Red Cross declared a blood “crisis” due to lack of supply – the second time this has occurred in its 150-year history – July 2026 Source: https://www.redcross.org/about-us/news-and-events/press-release/2026/red-cross-declares-national-blood-supply-crisis-urges-immediate-.html?srsltid=AfmBOoro3B6W9HSeChvpkC5q3iwy_i1-fMarBhhgFGuqJNjFFn7hfRqM C R I T I C A L M A R K E T : B L O O D 16
Page 17
C R I T I C A L M A R K E T : B L O O D Demand Rising Demographics are pulling demand up as supply flatlines — the case for preservation, yield and inventory. +30% Increase in population aged 65+ since 2013 +6% Gross U.S. population increase since 2013 −19% Decline in RBC units collected since 2013 Source: NBCUS, 2013–2023 (collections); U.S. Census Bureau (population). A demographic demand driver, not measured transfusion demand. 75 85 95 105 115 125 135 2013 2015 2017 2019 2021 2023 Index (2013 = 100) Population 65+ (demand driver) Total US population RBC units collected (supply) 17
Page 18
P R O B L E M 1 Chronic Platelets Shortages • Short shelf life leads to significant wastage - the US loses ~US$250m in wastage annually. • No FDA-approved cryopreserved platelet products is available on market <7 days platelet shelf life at room temperature P R O B L E M 2 End-of-Life Technology • The sole legacy RBC cryopreservation method is being discontinued • No approved replacement exists • THE U.S. BLOOD Network must adapt 2027 DEADLINE Legacy cryopreservation method phase-out C R I T I C A L M A R K E T : B L O O D Supply Constrained Two structural blood-market failures pose significant risk to supply as demand increases. 18
Page 19
C R I T I C A L M A R K E T : B L O O D Solving Increasing Supply Issues The goal: turn blood from an on-demand perishable product into a stable, consistent inventory asset. TODAY: A Perishable Supply Chain THE GOAL: An Inventory System Wastage recovered ~US$250m of platelets expire before use each year. Surge readiness Mass-casualty preparedness without experiencing variation in supply. Expanded reach Serving rural, remote and forward-deployed settings. 11.6 3.0 2.6 Red blood cells Plasma Platelets U.S. annual collection volume — units (millions) Frozen RBC share ~1% (~100,000 units, predominantly military). Platelet and plasma cryopreservation shares are indicative, based on clinical practice. 19
Page 20
C R I T I C A L M A R K E T : B L O O D Vitrafy Market Strategy A deliberate and targeted market entry strategy to unlock both military and civilian markets. FY24 –FY26 Military scientific validation In-vitro study I/II complete; 94.4% post-thaw quality on blood platelets. Technology validated and new market opportunities identified. ✓ FY26 Unlock civilian Urgent market need identified; partnerships commenced for potential infrastructure replacement with Vitalant and Hoxworth. ✓ FY27+ EXPANSION Targeting industry-wide market adoption Civilian and military blood — land and expand across sites and product use. Unlocks CGT raw materials: One solution, multiple uses. → → 20 Underway
Page 21
0 200 400 600 800 1000 1200 U.S. Blood Collection Network* C R I T I C A L M A R K E T : B L O O D The U.S. Blood Collection Network Concentrated blood supply networks, with a small number representing a material market opportunity. * Fixed sites only — excludes mobile collection centres used as part of market collections. Blood network concentration Over 1,000 fixed collection sites operate across the U.S. Examples of key blood network leaders: Independent Collection Centers Blood Centers of America members Note: industry names are illustrative of network scale and do not represent in-place agreements, except for Vitalant and Hoxworth. Independent Collection Centres 21
Page 22
C R I T I C A L M A R K E T : B L O O D Establishing a Commercial Beachhead Moving into FY27, Vitrafy has established a commercial beachhead it is looking to scale. Blood network partnerships secured • Exposure to ~17% of blood collection center sites¹ in the U.S. via executed partnerships • ~179 fixed-point collection sites covered by existing partnerships • Annual blood collections of ~2.4m² units across those sites • Focused on red blood cell and platelet products • 4 units to be deployed in FY27 1. 13% exposure is based on 179 combined fixed sites across Hoxworth, Vitalant and Versiti, against ~1,090 registered sites nationally. 2. Vitalant collects ~1.6m units p.a.; Hoxworth ~100,000 units p.a. 22 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Blood Collection Network Vitrafy Partnerships U.S. Blood Collection Market - Total Addressable Market Target Partners Secured Independent Collection Centres
Page 23
Outlook 27 Multiple, upcoming value inflection points.
Page 24
O U T L O O K Value Creation Roadmap Milestone-driven value creation across FY27, with near-term catalysts in both regulated and unregulated markets. COMPLETE Ecosystem validated • Product launch and U.S. arrival • USAISR Study II — 94.4% recovery • Civilian blood entry — Vitalant & Hoxworth • Human health partnerships secured Market willingness to pay • First 4 commercial units delivered • IMV Technologies global partnership • Animal revenue generating today FY27 — CLEAR MILESTONES AHEAD FDA approvals · land & expand · broad-scale adoption • FDA Guardion device listing (510K exempt) • Civilian & military blood market development • Red cell and platelet biologics milestones • U.S. commercial pipeline conversion across blood & CGT • Guardion device manufacturing in the US – at scale • Full U.S. customer-facing operation • IMV partnership growth • U.S. staff scale-up and CEO relocation to the US 24
Page 25
A S X : V F Y | T H E W I N D O W I S N O W Cryopreservation is broken. Vitrafy is the fix. Validated technology 94.4% post-thaw recovery, best-in-class — a competitive advantage and moat. Clear market need A forcing event: no approved alternative, ahead of the 2027 deadline. Tailwind: growth in personalised medicine in CGT Commercial ready Revenue generating today; scaling animal reproduction and human health. Deliver value Improving customer and patient outcomes through better-preserved materials. Pioneering technology, preserving life. 29
Page 26
Appendix 26
Page 27
C R Y O P R E S E R V A T I O N Essential Science, Ageing Infrastructure Cryopreserving biological materials underpins modern healthcare —current market technology has largely unchanged since the 1960s. W H A T I T I S Holding biology at ultra-low temperature The science of preserving cells, tissue and blood at ultra- low temperatures so they remain viable for later clinical or commercial use. P R I O R I T Y M A R K E T S Cell & gene therapies Blood products Animal reproduction T H E C U R R E N T S T A T E Isolated The stand-alone freezer is still the gold standard — disconnected from the workflow around it. Blind Little or no data capture to evidence GMP compliance or support FDA submissions. Damaging Liquid nitrogen and toxic cryoprotectants are mandatory from freeze through to thaw. Costly Lost viability, manual handling and wasted product erode quality, time and margin. 27
Page 28
T H E P L A T F O R M Cryopreservation-as-an-Ecosystem One integrated platform — hardware, software and consumables — that embeds, then expands. Q U A L I T Y D R I V E R Guardion LN2-free controlled-rate freezer — the entry point that embeds Vitrafy in the customer workflow. D A T A M O A T LifeChain Cloud orchestration built to 21 CFR Part 11. Data compounds with every cycle. E C O S Y S T E M C O N N E C T I O N Thawing Precision thawing to transfusion-ready temperature in minutes, beyond specialist labs. R E V E N U E D R I V E R Consumables Single-use consumables — per-unit economics that scale with throughput. 28 Initial Commercial Products Future Product Releases
Page 29
Recurring Revenue Model Recurring managed-service economics that compound with every installed device. Installed Device Count > Recurring Monthly Service Fee + Consumable fee 01 Managed Service H A R D W A R E + S O F T W A R E + S E R V I C E Guardion freezer access LifeChain Software & service support Thawing units included Open-source use on all approved applications 02 Smart Consumables P E R - C Y C L E R E V E N U E Single-use consumables across Animal & Human Sold separately to managed service Compounding upside on base fee 03 Compounding Moat S W I T C H I N G C O S T LifeChain data enables continuous improvement Outcomes intelligence hardens lock-in Strengthen competitive moat 29
Page 30
30 Priority Verticals Strategies and Catalysts ▪ Food security and production ▪ Increased beef & fish consumption ▪ Population growth ▪ Technology obsolescence ▪ Structural supply shortages ▪ Global instability & disaster events ▪ Preparedness events (Olympics) ▪ Requires standardisation ▪ More Cells = More Value ▪ Cost prohibitive therapies limiting scale Animal Reproduction Blood Cell & Gene Therapy Growth Catalysts ▪ Highly concentrated market share ▪ Global partnership with industry leader ▪ Military into civilian ▪ Multi-use solution across various Blood components ▪ Drug Manufacturer collaboration ▪ Target pre or early clinical trials ▪ End-user driven adoption ▪ First Customer: Huon Aquaculture ▪ Secured Global Partner: ▪ IMV Technologies ▪ Government & Industry bodies ▪ Civilian & Military Blood collection ▪ Secured partnership with Vitalant, Hoxworth and Versiti ▪ Drug Contract Development & Manufacturing Organizations (CDMO) ▪ Civilian Blood Collection ▪ Secured partnership with Charter Medical GTM Strategy One solution, multiple go-to-market applications. Vitrafy has prioritised three areas. Traction